Home Tags retatrutide

Tag: retatrutide

Lilly’s investigational GLP-1 reduces AHI by up to 36 events per hour in OSA patients

June 8, 2026HME News Staff

INDIANAPOLIS – Eli Lilly, the maker of Zepbound and Foundayo, has announced positive results from Phase 3 trials of retatrutide, an investigational GLP-1, showing substantial weight loss along with meaningful improvements across knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and Type 2 diabetes – common obesity-related conditions. "Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos,"...

Eli Lilly, GLP-1, Obstructive Sleep Apnea (OSA), retatrutide